Cro has become an important way to reduce the cost of new drug research and development and to achieve rapid marketing

[market analysis of pharmaceutical Station] with the continuous promotion of measures such as the reform of drug examination to encourage innovation, the acceleration of new drug market examination and approval, and the consistency evaluation, the pharmaceutical market is facing reconstruction, and the competition among pharmaceutical enterprises is becoming increasingly fierce CrO (drug R & D outsourcing service) has the advantages of specialty and is becoming an important way for drug companies to reduce the cost of drug R & D, shorten the time of drug R & D, and realize the rapid listing of new drugs It is reported that cro industry is a new industry in China At first, cro industry originated from developed countries in Europe and the United States However, due to high R & D costs, cro industry has gradually shifted to emerging developing countries such as China and India According to the industry, the competition of new drug R & D is about speed and capital "Using cro to carry out projects, on the one hand, can improve the capital utilization rate, put more funds on the project products, and reduce the investment in fixed assets such as instrument and equipment plants On the other hand, it will take a long time to build the R & D center and R & D team R & D outsourcing can save the time of drug R & D, but also help start-ups reduce risks " For new drug R & D enterprises, how to reduce R & D cost and R & D risk is also a key issue, in addition to competing speed and capital Cro is a powerful tool for pharmaceutical companies to solve these problems, accelerate the research and development of new drugs, and further seize market share China's pharmaceutical R & D industry started late, with insufficient technical capacity and experience, and less R & D investment, but in recent years, it has changed significantly, and there is a large space for improvement With the improvement of R & D strength of domestic pharmaceutical enterprises and the strengthening of supervision on generic drugs in terms of policies, such as the development of generic drug consistency evaluation, the self-examination of clinical trial data and the promotion of verification, the investment in R & D of Chinese pharmaceutical enterprises will continue to increase Under the background that the country gradually advocates the independent innovation of drugs and more and more attention is paid to innovative drugs, the R & D investment in China's pharmaceutical industry is growing, while the cro industry will also benefit a lot   It is reported that in terms of policies, cro industry has gained more favorable conditions in recent years, and the industry has ushered in good development opportunities In particular, China has broken the development situation of relying solely on generic drugs in the past, encouraged the rise of the development trend of innovative drugs, so that cro Enterprises have more opportunities to participate in the whole process of enterprise research and development, including molecular screening modeling, safety assessment, process improvement, and clinical C RO et al At the same time, the promotion of consistency evaluation also creates a rich order basis for cro enterprises It is reported that after the "4 + 7" volume procurement, the profits of generic pharmaceutical enterprises have declined, and enterprises have to carry out strategic transformation, and they are more optimistic about cro enterprises In this context, cro industry will usher in more development space and fierce competition In addition, centralized procurement and follow-up fee control by the medical insurance bureau are the general trend In the future, the product force under the pressure of drug price is the core More pharmaceutical enterprises return to the nature of R & D, and the cro industry will continue to be optimistic On the whole, under the dual factors of continuous growth of R & D investment of pharmaceutical enterprises and increasing recognition of cro industry, the R & D service outsourcing market is booming, and the market scale will continue to increase in the future According to statistics, the market size of China's cro industry in 2013 was about 22.93 billion yuan, increasing to 63.31 billion yuan in 2017, with a compound growth rate of 22.4% in 2013-2017 With the rapid development of China's pharmaceutical industry, the market scale of cro industry will expand year by year, and the change of industrial pattern will benefit the leading enterprises of cro industry.